MediWound Highlights Consensus Supporting Debridement Strategy
Summary: MediWound announced publication of a peer-reviewed supplement in WOUNDS featuring findings from a U.S.-based multidisciplinary consensus panel on debridement in chronic wounds. The panel redefines debridement as a biologically active process that drives healing by reducing biofilm and bacterial load, rather than mere removal of non-viable tissue. Experts recommend initiating treatment with effective, less invasive modalities when clinically appropriate, reserving surgical debridement for specific indications. The consensus highlights the gap in single-modality solutions and underscores the need for easy-to-use, clinically effective first-line therapies. MediWound’s enzymatic products (NexoBrid for burns; EscharEx in development for chronic wounds) align with this framework, with ongoing Phase III trials in venous leg ulcers and planned studies in diabetic foot and pressure ulcers.
Key Highlights:
- Debridement reframed as active intervention targeting biofilm and bacteria
- Preference for less invasive approaches first; surgical reserved for indicated cases
- Supports enzymatic debridement strategies like bromelain-based therapies
- Implications for standardized, effective chronic wound management
Keywords: debridement consensus, chronic wound debridement, EscharEx, biofilm management